Thymosin Alpha-1 vs Thymosin Beta-4
Thymic Peptide · Thymic Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
Thymosin Alpha-1
A 28-amino-acid immune modulator that enhances T-cell function; internationally approved as Zadaxin for hepatitis and immune support.
Thymosin Beta-4
A 43-amino-acid tissue repair peptide that sequesters actin to enable cell migration; parent molecule of the TB-500 research peptide.
Thymosin Alpha-1
856 studies
61 human trials
Not FDA-Approved
Thymosin Beta-4
1038 studies
13 human trials
Not FDA-Approved
What it does
Thymosin Alpha-1
Holds the broadest international clinical adoption of any thymic peptide. Approved as Zadaxin in over 35 countries for hepatitis B, hepatitis C, and immune support during chemotherapy. FDA orphan-drug designation in the United States. Works by activating dendritic cells (the immune system's sentinel cells) through Toll-like receptor 9, which then drives T-cell maturation. The published mechanism pushes the immune system toward attacking infected or abnormal cells directly, rather than primarily producing antibodies.
Thymosin Beta-4
Sequesters actin inside cells, which allows cells to migrate toward damaged tissue and begin repair. The full-length parent molecule that TB-500 is derived from. Found naturally throughout the body at high concentrations.
How it works
Thymosin Alpha-1
Thymosin Alpha-1 binds Toll-like receptors (TLR2 and TLR9) on dendritic cells, the immune system's sentinel cells that present invaders to T-cells. That binding tilts the immune balance toward cell-mediated (Th1) responses over antibody-dominated (Th2) responses. It also activates natural killer cells and increases interferon production. The restorative profile, rather than broad stimulation, is what distinguishes it: benefit appears in immunocompromised populations (chronic hepatitis, cancer adjunct, elderly vaccine recipients) but is less clear in healthy adults with normal immune function.
Thymosin Beta-4
Thymosin Beta-4 is a 43-amino-acid peptide that binds monomeric actin (G-actin), preventing it from polymerizing prematurely. By controlling when and where actin assembles, Thymosin Beta-4 enables the cytoskeletal reorganization cells need to move, divide, and form new blood vessels. This mechanism drives tissue repair through cell migration, angiogenesis, and anti-inflammatory signaling. TB-500, the commercially available research peptide, is a 4-amino-acid synthetic fragment corresponding to the active site of Thymosin Beta-4, not the full molecule.
How often
Thymosin Alpha-1
Subcutaneous injection in clinical trials and approved international use. Frequency and duration vary by indication in published trial protocols. Thymosin Alpha-1 is not FDA-approved in the United States; international use as Zadaxin follows country-specific prescribing guidelines.
Thymosin Beta-4
In published research, Thymosin Beta-4 has been studied in animal models of wound healing, cardiac injury, corneal repair, and neurological damage. No FDA-approved product exists for the full-length molecule. Clinical development programs for ophthalmic indications (RGN-259) have been conducted but have not yet resulted in FDA approval.
How strong
Thymosin Alpha-1
The most clinically validated peptide in PSI's library outside FDA-approved compounds. 856 published studies including 61 human trials. The strongest evidence is in chronic hepatitis B, where controlled trials show improved viral clearance when combined with interferon therapy. Cancer immunotherapy adjunct and vaccine adjuvant evidence is developing across multiple indications.
Thymosin Beta-4
Extensive preclinical data across multiple tissue types: cardiac, dermal, corneal, and neurological repair models. The actin-sequestering mechanism is well-characterized biochemically. The RGN-259 ophthalmic program generated human safety and preliminary efficacy data. TB-500, the fragment form, is more widely available in research peptide markets than full-length Thymosin Beta-4.
Main tradeoff
Thymosin Alpha-1
Approved in more than 35 countries since 1996; not approved in the United States. Both are true simultaneously, and the gap reflects an incomplete U.S. FDA approval process rather than a clinical failure. The EMA declined approval in 2006 on trial-design grounds. Whether the cancer immunotherapy adjunct evidence holds up in large checkpoint-inhibitor-era trials is empirically open. Whether healthy adults with normal immune function derive meaningful benefit is not established; most evidence is in immunocompromised populations.
Thymosin Beta-4
The full-length Thymosin Beta-4 molecule has more preclinical data than TB-500 but is harder to source and more expensive. TB-500, the fragment, is widely available but represents only the active site, not the complete signaling molecule. Whether the fragment recapitulates the full molecule's effects in all tissue contexts is not definitively established. Neither form is FDA-approved for any therapeutic indication.
Best for
Thymosin Alpha-1
- Research interest in immune modulation through thymic peptide signaling
- Research focused on hepatitis B adjunct therapy where international approval evidence applies
- Research comparing immune-restorative versus immune-stimulatory compound profiles
Thymosin Beta-4
- Research comparing full-length Thymosin Beta-4 signaling versus the TB-500 active fragment
- Research on actin-sequestering mechanisms in tissue repair and cell migration
- Research on endogenous wound-healing peptides and their therapeutic potential
How to choose
A good fit for Thymosin Alpha-1
- Research on adaptive immune modulation and T-cell function enhancement
- Research contexts where international clinical approval (Zadaxin, 35+ countries) carries weight
- Research on immune support for chronic viral infections or immune deficiency
A good fit for Thymosin Beta-4
- Research on actin-sequestering mechanisms in cell migration and tissue repair
- Research on cardiac, dermal, or musculoskeletal injury repair models
- Research comparing full-length Thymosin Beta-4 versus the TB-500 synthetic fragment
Consider both across time
Thymosin Alpha-1 and Thymosin Beta-4 are not alternatives to each other. They address entirely different biological systems: immune modulation versus tissue repair. The shared 'thymosin' prefix reflects their historical discovery in thymus extracts, not shared function. Choosing between them depends on whether the research question is about immune function or tissue repair. They are complementary rather than competitive.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- TLR2 Receptor
- TLR9 Receptor
- TLR2 Receptor expressed on Dendritic Cells; TLR9 Receptor expressed on Dendritic Cells
- Dendritic Cells connects to T-cell Maturation
- T-cell Maturation connects to Th1 Immune Response
- Dendritic Cells connects to Natural Killer Cells
- Natural Killer Cells connects to Interferon Production
- G-Actin Sequestration
- G-Actin Sequestration enables Cell Migration
- G-Actin Sequestration promotes Angiogenesis
- G-Actin Sequestration activates Hair Follicle Stem Cell Activation
- Cell Migration connects to Tissue Repair; Angiogenesis connects to Tissue Repair
- Hair Follicle Stem Cell Activation connects to Tissue Regeneration
Thymosin Alpha-1 binds TLR2 and TLR9 receptors on dendritic cells to promote T-cell maturation and tilt the immune balance toward cell-mediated (Th1) responses.
Thymosin Beta-4 sequesters G-actin to enable cytoskeletal reorganization, cell migration, and tissue repair.
Research Evidence
Thymosin Alpha-1 has more clinical evidence: international approval as Zadaxin in 35+ countries for chronic hepatitis B and immune support, with decades of clinical use data. Thymosin Beta-4 has primarily preclinical evidence across multiple tissue repair models, with human data from the RGN-259 ophthalmic development program. The evidence structures reflect the different clinical development histories, not relative merit.
- 1.
For immune support, TA1 is the appropriate compound with clinical validation.
- 2.
For tissue repair and wound healing, TB4 (or TB-500) is the relevant option.
- 3.
Do not substitute one for the other, they serve completely different functions.
- 4.
The name similarity is misleading, always verify which thymosin is being discussed.
Key Limitations
- •Not interchangeable despite similar names.
- •Different biological functions, different evidence levels.
- •TB4 clinical development has been slower than expected.
- •Neither is FDA-approved in the US.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Thymosin Alpha-1
"Thymosin alpha-1 is the best peptide for immune support"
Supported by published data
"People use it to prevent getting sick during travel"
Plausible but unproven
"It helped during long COVID recovery"
Anecdotal only
Thymosin Beta-4
"Thymosin Beta-4 is the same thing as TB-500"
Partially accurate
"There's an eye drop version in clinical trials"
Supported by evidence
Safety Comparison
Thymosin Alpha-1 has well-characterized safety from international clinical use: generally well-tolerated with injection site reactions as the primary reported concern. Thymosin Beta-4 has favorable preclinical safety data; the RGN-259 program provided some human safety characterization. Neither is FDA-approved. Both are derived from endogenous human proteins.
Thymosin Alpha-1
Approved in 30+ countries as Zadaxin. Decades of clinical safety data. Minimal side effects.
Thymosin Beta-4
Clinical trial data for corneal healing. Generally well-tolerated. Limited long-term safety data.
What the Research Suggests
The names are similar. The functions are not. Thymosin Alpha-1 for immune modulation. Thymosin Beta-4 for tissue repair. Every discussion about 'thymosins' should specify which one.